Skip to main content

Procter & Gamble to Use Osteoporosis Targets Identified by Sequenom

NEW YORK, Dec. 18 (Genome Web News) - Sequenom has licenced to Procter & Gamble Pharmaceuticals an undisclosed number of osteoporosis targets against which the drug company hopes to develop new therapeutics, the companies said today.

 

P&G will validate targets in osteoporosis biological and animal models to identify screening candidates. Sequenom stands to gain royalties on product sales, and is entitled to receive license and milestone payments. Sequenom will also retain all diagnostic rights to the targets.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.